Esther Latres

USPTO Granted Patents = 10 (Patent Applications = 8)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 132(Granted Patents)

Company Filing History:

9 out of 1,343

Regeneron Pharmaceuticals, Inc.

Years Active: 2004-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11655291 - Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A (2023-05-23),

2. 10526403 - Anti-activin A antibodies and uses thereof (2020-01-07),

3. 10400036 - Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A (2019-09-03),

4. 9890212 - Antibodies to human GDF8 (2018-02-13),

5. 9718881 - Anti-Activin A antibodies and uses thereof (2017-08-01),

6. 9260515 - Antibodies to human GDF8 (2016-02-16),

7. 8871209 - Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A (2014-10-28),

8. 8840894 - Antibodies to human GDF8 (2014-09-23),

9. 7632503 - Method of treating a muscle-related condition with modified IGF1 polypeptides (2009-12-15),

10. 6720181 - Ubiquitin ligases as therapeutic targets (2004-04-13),

Title: Esther Latres: Innovator in Muscle Mass and Strength Enhancement

Introduction

Esther Latres is a prominent inventor based in New York, NY (US), known for her significant contributions to the field of muscle mass and strength enhancement. With a total of 10 patents, her work focuses on innovative compositions and methods that target specific proteins to improve muscle health.

Latest Patents

Latres' latest patents include groundbreaking inventions such as "Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A." This invention provides compositions that involve specifically antagonizing GDF8 and Activin A, utilizing binding proteins to create effective treatments for conditions characterized by reduced muscle mass or strength. Another notable patent is "Anti-activin A antibodies and uses thereof," which details fully human antibodies that bind to Activin A with high affinity. These antibodies are designed to treat various disorders associated with decreased muscle mass or strength, including sarcopenia and cachexia.

Career Highlights

Throughout her career, Esther Latres has worked with esteemed organizations such as Regeneron Pharmaceuticals, Inc. and New York University. Her innovative research has positioned her as a leader in the field of muscle health and therapeutic development.

Collaborations

Latres has collaborated with notable colleagues, including Trevor Stitt and Jesper Gromada, contributing to the advancement of her research and the development of her patents.

Conclusion

Esther Latres is a trailblazer in the field of muscle mass and strength enhancement, with a strong portfolio of patents that reflect her dedication to improving health outcomes. Her innovative work continues to pave the way for new treatments and therapies in muscle health.

This text is generated by artificial intelligence and may not be accurate.